Current Bisphosphonates News and Events | Page 2

Current Bisphosphonates News and Events, Bisphosphonates News Articles.
Sort By: Most Relevant | Most Viewed
Page 2 of 6 | 208 Results
Expert panel evaluates role of osteoporosis medications in fracture healing
Using a structured expert-opinion process, an International Osteoporosis Foundation expert panel has written a consensus report on the use of osteoporosis medications in patients with recent fracture and the potential role of these medications in promoting fracture healing. The report will help set the scene for both improved patient care and good clinical study design for future research. (2016-04-27)

Herbert A. Fleisch ESCEO-IOF Medal 2016 awarded to Professor René Rizzoli
Professor René Rizzoli, Emeritus Professor of Medicine at University Hospitals of Geneva has been awarded the prestigious Herbert A. Fleisch ESCEO-IOF Medal during the opening ceremony of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. (2016-04-14)

To treat a leading cause of osteoporosis, surgery is better than widely used medications
A leading cause of the bone-loss disease osteoporosis is hyperparathyroidism. Doctors commonly treat this using a class of prescription drugs called bisphosphonates, which are supposed to strengthen bones. A UCLA study found those drugs actually increase the risk of fracture, meaning that taking them is worse than doing nothing at all. The research also revealed that patients who have surgery to remove the overactive parathyroid glands have fewer subsequent bone fractures. (2016-04-04)

Surgery associated with reduced fractures in patients with hyperparathyroidism
Surgery to remove the parathyroid was associated with reduced fracture risk in patients with primary hyperparathyroidism, whereas bisphosphonate treatment was associated with increased bone mineral density but not fewer fractures. The observational study was published in Annals of Internal Medicine. (2016-04-04)

Drugs that treat osteoporosis also can cause small risk of thigh bone fractures
Osteoporosis drugs have significantly reduced the risk of bone fractures for millions of people, but also have been linked to unusual fractures of the femur (thigh bone). (2016-02-29)

Task force provides guidance on use of osteoporosis drugs
A new report by a task force of the American Society for Bone and Mineral Research provides guidance on the use of bisphosphonates, which are the most commonly used medications for osteoporosis. (2016-01-19)

Experts question automatic osteoporosis drug holidays
A new editorial published in the journal Osteoporosis International urges physicians to individualize treatment decisions based on their patients' fracture risk, rather than automatically interrupting or stopping bisphosphonate therapy after five or three years. (2016-01-04)

Denosumab improves disease-free survival for postmenopausal patients w HR+ breast cancer
Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (2015-12-09)

How to wake a sleeping cancer cell -- and why you might want to
Cancer cells that lie 'snoozing' in the skeleton can be awakened by changes in the bone that surrounds them, Australian scientists have shown. In a world first, researchers from the Garvan Institute of Medical Research have used state-of-the-art microscopy techniques to watch cancer cells sleep within living bone over a period of months. They show that cancer cells can be 'woken up' when bone tissue is broken down around them, suggesting new possibilities for treating metastatic cancer in bone. (2015-12-03)

Two MD Anderson faculty named as prestigious AAAS Fellows
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have earned two scientists at The University of Texas MD Anderson Cancer Center membership in a notable association of scholars. (2015-11-23)

The use of bisphosphonates is associated with an increased risk of atypical hip fractures
The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint. It has been established thus in the Ph.D. thesis by Javier Gorricho, a graduate in pharmacy, read at the Public University of Navarre. The author advocates encouraging other preventive measures such as 'strategies to reduce falls and an active lifestyle to improve bone density and health.' (2015-09-22)

Estrogen-suppressing drugs substantially reduce breast cancer deaths
A class of hormonal drugs called aromatase inhibitors substantially reduce the risk of death in postmenopausal women with the most common type of breast cancer, a major study of more than 30,000 women shows. The research underlines the importance of aromatase inhibitors in the treatment of oestrogen receptor (ER)-positive breast cancer -- and shows they reduce risk of death by significantly more than the older hormonal treatment tamoxifen. (2015-07-23)

The Lancet: New studies show that 2 classes of inexpensive generic drugs can reduce breast cancer deaths
Two new studies, both published in The Lancet, suggest that two different classes of drugs, aromatase inhibitors and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer. Moreover, the researchers suggest that the two types of drug can be used together, increasing the benefits while also decreasing some side-effects. (2015-07-23)

Use of osteoporosis drugs have dropped following media reports of safety concerns
Following a decade of steady growth, use of bisphosphonates -- medications that are effective for treating osteoporosis -- declined in the United States by more than 50 percent from 2008 to 2012. (2015-06-15)

Brittle bone disease: Drug research offers hope
New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating bone disorder that that is present from birth. (2015-03-31)

Routine bisphosphonate treatment for women over age 65
Osteoporosis is a disease of progressive bone loss affecting more than 44 million Americans and contributing to an estimated 2 million bone fractures each year. (2015-03-24)

Time for balance? Preventing atypical femoral fractures related to bisphosphonates
Two recent articles, one publishing in JBJS Reviews; the other published in JBJS Case Connector, examine the relationship between bisphosphonates and atypical fractures of the femur. (2015-03-04)

Bone loss drugs may help prevent endometrial cancer
A new analysis suggests that women who use bisphosphonates -- medications commonly used to treat osteoporosis and other bone conditions -- have about half the risk of developing endometrial cancer as women who do not use the drugs. (2014-12-22)

Study examines use of drugs to strengthen bones for men receiving ADT
Although some guidelines recommend use of bisphosphonates, a class of drugs used to strengthen bone, for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the Dec. 3 issue of JAMA. (2014-12-02)

Widely used osteoporosis drugs may prevent breast, lung and colon cancers
The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers. (2014-12-01)

Experts suggest single dose IV medication as first-choice treatment for Paget's disease
The Endocrine Society today issued a Clinical Practice Guideline for the diagnosis and treatment of Paget's disease of the bone, a condition where one or more bones in the body become oversized and weak. (2014-11-19)

Bone drug should be seen in a new light for its anti-cancer properties
Australian researchers have shown why calcium-binding drugs commonly used to treat people with osteoporosis, or with late-stage cancers that have spread to bone, may also benefit patients with tumours outside the skeleton, including breast cancer. (2014-11-05)

Osteoporosis treatment may also benefit breast cancer patients
Treatment approaches to reduce the risk of bone metastasis associated with breast cancer may be one step closer to becoming a reality. According to a study led by the MUHC, findings show that medication used to treat bone deterioration in post-menopausal women may also slow skeletal metastasis caused from breast cancer. This study, published in the JNCI, is among the first to link bisphosphonate use with improved survival in women with breast cancer. (2014-10-02)

Bone drugs may not protect osteoporotic women from breast cancer
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco. (2014-08-11)

Bisphosphonates for osteoporosis not associated with reduced breast cancer risk
An analysis of data from two randomized clinical trials finds that 3-4 years of treatment with bisphosphonates to improve bone density is not linked to reduced risk of invasive postmenopausal breast cancer. (2014-08-11)

Scientists engineer nanoparticles to prevent bone cancer, strengthen bones
A research collaboration between Brigham and Women's Hospital and Dana-Farber Cancer Institute has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression. (2014-06-30)

American Society of Clinical Oncology recognizes MD Anderson leaders for their contributions to cancer research
As the American Society of Clinical Oncology celebrates its 50th anniversary, the organization named former MD Anderson president John Mendelsohn, M.D., Waun Ki Hong, M.D., and Gabriel Hortobagyi, M.D. to its list of luminaries. (2014-06-02)

Researchers take a major step towards better diagnosis and treatment of osteoporosis
A new target for the treatment of osteoporosis has been discovered by a group of researchers in The Netherlands and in Germany. Studies in zebrafish and mice have shown that injection of human plastin 3 (PLS3) or related proteins in zebrafish where PLS3 action has been suppressed can replace its loss and repair the bone development anomalies associated with this deficiency. Furthermore, overexpression of human (PLS3) in normal mice had a significant impact on bone development and maintenance, making them more resistant to fractures. (2014-05-30)

Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without comp
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, women may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center. (2014-05-30)

Study looks at predicting fracture risk after women stop bisphosphonate therapy
Age and testing of hip bone mineral density when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures over the next five years. (2014-05-05)

New model can predict therapy outcomes in prostate cancer with bone metastasis
A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American Association for Cancer Research. (2014-05-01)

Osteoporosis drugs appear to impede cell membrane repair
A class of drugs widely used to treat osteoporosis appears to impede a cell's ability to repair a protective outer membrane that helps determine what enters and exits, researchers report. (2014-04-14)

IOF Medal of Achievement awarded to professor Rene Rizzoli
Today, at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, professor Rene Rizzoli of the University Hospital of Geneva was awarded the International Osteoporosis Foundation Medal of Achievement. The award is presented annually by IOF to honor an individual researcher who has significantly advanced the field of osteoporosis through his original and outstanding scientific contributions. (2014-04-04)

Radium-223 dichloride in prostate cancer: Major added benefit for certain patients
Trastuzumab emtansine: indication of major added benefit in metastatic breast cancer with previous anthracycline therapy. Appropriate comparator therapy was only complied with in one out of four subpopulations with advanced or metastatic HER2-positive breast cancer. (2014-04-03)

Loyola study provides guidance on drug holidays from popular osteoporosis treatments
Doctors commonly recommend drug holidays, or breaks, from certain osteoporosis drugs due to the risks associated with these treatments. Yet little has been known about the ideal duration of the holidays and how best to manage patients during this time. (2014-01-14)

New materials with potential biomedical applications
New uses for bisphosphonates were discovered, as their ability to form physical gels in pure water was reported for the first time in a recent study performed in collaboration with the Universities of Jyvaskyla and Eastern Finland. (2013-11-21)

New studies may explain fractures in some who take osteoporosis drugs
Research with baboons at the Texas Biomedical Research Institute in San Antonio may help explain why some people who take bone-strengthening drugs like bisphosphonates are at-risk for atypical fractures in the long bones in their legs. (2013-11-14)

CNIC researchers find a possible treatment for one of the main symptoms of premature aging disease
Working with an animal model, the team of scientists at the Centro Nacional de Investigaciones Cardiovasculares have discovered that a deficit in the production of pyrophosphate provokes excessive vascular calcification, one of the most important symptoms of the premature aging disease Hutchinson-Gilford progeria syndrome, also known as progeria. Excess calcium in the arterial wall is also a typical feature of physiological aging in the general population. (2013-06-17)

Osteoporosis drug aids young people with cystic fibrosis not helped by standard treatments
The first randomised trial to investigate the treatment of low bone density in young people with cystic fibrosis (CF), published Online First in The Lancet Respiratory Medicine, provides compelling evidence that alendronate (a drug that curbs bone loss) is safe and can help increase bone mineral density in young patients with CF after standard treatment with calcium and vitamin D has failed. (2013-06-01)

Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos
Professor Socrates Papapoulos, a long standing member of the IOF Board and leading researcher at the Leiden University Medical Center, has been named the recipient of the prestigious Pierre Delmas Award. The award was presented today at the European Congress on Osteoporosis & Osteoarthritis, currently being held in Rome, Italy. (2013-04-18)

Page 2 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to